U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C38H46Cl2N6O8S
Molecular Weight 817.778
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BIO-5192

SMILES

CC(C)C[C@H](N(C)C(=O)CC1=CC=C(NC(=O)NC2=CC=CC=C2C)C=C1)C(=O)NCC[C@H](NC(=O)[C@@H]3CCCN3S(=O)(=O)C4=CC(Cl)=CC(Cl)=C4)C(O)=O

InChI

InChIKey=MNQBPRHHZPXCKZ-ZDCRTTOTSA-N
InChI=1S/C38H46Cl2N6O8S/c1-23(2)18-33(45(4)34(47)19-25-11-13-28(14-12-25)42-38(52)44-30-9-6-5-8-24(30)3)35(48)41-16-15-31(37(50)51)43-36(49)32-10-7-17-46(32)55(53,54)29-21-26(39)20-27(40)22-29/h5-6,8-9,11-14,20-23,31-33H,7,10,15-19H2,1-4H3,(H,41,48)(H,43,49)(H,50,51)(H2,42,44,52)/t31-,32-,33-/m0/s1

HIDE SMILES / InChI

Molecular Formula C38H46Cl2N6O8S
Molecular Weight 817.778
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including http://adisinsight.springer.com/drugs/800019793

BIO-5192 is a highly selective and potent (KD of <10 pM) inhibitor of integrin alpha 4 beta 1. The high affinity for integrin alpha 4 beta 1 results from an extremely slow dissociation rate of the inhibitor from the integrin/inhibitor complex, with a dissociation half-life of >12 h for both the unactivated and activated integrin. Preclinical trials in multiple sclerosis in USA were underway, but no recent development of BIO-5192 or its pegylated form has been reported; it appears that development has been discontinued.

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
An integrin inhibiting molecule decreases oxidative damage and improves neurological function after spinal cord injury.
2008 Dec
Patents

Sample Use Guides

Rats: rats were treated intravenously with BIO-5192 (10 mg/kg)
Route of Administration: Intravenous
BIO-5192 (1 ug/mL) reduced both untreated and phorbol 12-myristate 13-acetate–stimulated murine A20 lymphoma cell binding to fibronectin-coated plates by 43% and 36%, respectively, indicating that BIO-5192 blocks binding to multiple activation states of VLA-4
Substance Class Chemical
Created
by admin
on Sat Dec 16 09:27:34 GMT 2023
Edited
by admin
on Sat Dec 16 09:27:34 GMT 2023
Record UNII
55W0N209OS
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BIO-5192
Common Name English
BUTANOIC ACID, 2-((((2S)-1-((3,5-DICHLOROPHENYL)SULFONYL)-2-PYRROLIDINYL)CARBONYL)AMINO)-4-(((2S)-4-METHYL-2-(METHYL(2-(4-((((2-METHYLPHENYL)AMINO)CARBONYL)AMINO)PHENYL)ACETYL)AMINO)-1-OXOPENTYL)AMINO)-, (2S)-
Systematic Name English
AMD-15057
Code English
BUTANOIC ACID, 1-((3,5-DICHLOROPHENYL)SULFONYL)-L-PROLYL-N4-(N-METHYL-N-((4-((((2-METHYLPHENYL)AMINO)CARBONYL)AMINO)PHENYL)ACETYL)-L-LEUCYL)-2,4-DIAMINO-, (2S)-
Systematic Name English
BUTANOIC ACID, 2-((((2S)-1-((3,5-DICHLOROPHENYL)SULFONYL)-2-PYRROLIDINYL)CARBONYL)AMINO)-4-(((2S)-4-METHYL-2-(METHYL((4-((((2-METHYLPHENYL)AMINO)CARBONYL)AMINO)PHENYL)ACETYL)AMINO)-1-OXOPENTYL)AMINO)-, (2S)-
Systematic Name English
Code System Code Type Description
CAS
327613-57-0
Created by admin on Sat Dec 16 09:27:34 GMT 2023 , Edited by admin on Sat Dec 16 09:27:34 GMT 2023
PRIMARY
PUBCHEM
10350459
Created by admin on Sat Dec 16 09:27:34 GMT 2023 , Edited by admin on Sat Dec 16 09:27:34 GMT 2023
PRIMARY
FDA UNII
55W0N209OS
Created by admin on Sat Dec 16 09:27:34 GMT 2023 , Edited by admin on Sat Dec 16 09:27:34 GMT 2023
PRIMARY
Related Record Type Details
ACTIVE MOIETY